MetLife Investment Management LLC Invests $103,000 in Contineum Therapeutics, Inc. (NASDAQ:CTNM)

MetLife Investment Management LLC purchased a new stake in Contineum Therapeutics, Inc. (NASDAQ:CTNM) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 7,029 shares of the company’s stock, valued at approximately $103,000.

Several other large investors have also recently bought and sold shares of the stock. Marshall Wace LLP bought a new stake in Contineum Therapeutics in the 4th quarter valued at $159,000. Strategies Wealth Advisors LLC bought a new stake in shares of Contineum Therapeutics in the fourth quarter valued at about $366,000. Barclays PLC boosted its position in shares of Contineum Therapeutics by 96.0% in the fourth quarter. Barclays PLC now owns 16,286 shares of the company’s stock valued at $239,000 after acquiring an additional 7,978 shares during the period. Legal & General Group Plc grew its stake in shares of Contineum Therapeutics by 74.0% in the fourth quarter. Legal & General Group Plc now owns 3,631 shares of the company’s stock valued at $53,000 after acquiring an additional 1,544 shares in the last quarter. Finally, ADAR1 Capital Management LLC increased its position in Contineum Therapeutics by 817.1% during the fourth quarter. ADAR1 Capital Management LLC now owns 82,234 shares of the company’s stock worth $1,205,000 after acquiring an additional 73,267 shares during the period.

Contineum Therapeutics Stock Down 2.0 %

Contineum Therapeutics stock opened at $3.87 on Friday. The stock has a market cap of $100.12 million and a PE ratio of -0.79. Contineum Therapeutics, Inc. has a 12-month low of $3.64 and a 12-month high of $22.00. The business’s 50-day moving average price is $5.60 and its two-hundred day moving average price is $10.42.

Wall Street Analyst Weigh In

A number of analysts have issued reports on CTNM shares. Robert W. Baird cut their price objective on shares of Contineum Therapeutics from $32.00 to $16.00 and set an “outperform” rating for the company in a report on Friday, March 7th. Jones Trading initiated coverage on Contineum Therapeutics in a research note on Thursday, March 13th. They issued a “buy” rating and a $23.00 price target for the company. Finally, Morgan Stanley restated an “overweight” rating and set a $25.00 price objective on shares of Contineum Therapeutics in a research note on Friday, March 7th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Contineum Therapeutics presently has a consensus rating of “Buy” and an average target price of $23.75.

About Contineum Therapeutics

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).